Recurrent Small Cell Lung Cancer (SCLC) Terminated Phase 1 Trials for Nivolumab (DB09035)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Small Cell Lung Cancer Recurrent / Refractory Small cell lung cancer / Recurrent Small Cell Lung Cancer / Recurrent Lung Small Cell Carcinoma / Recurrent Small Cell Lung Carcinoma

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04610658Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTreatment